EUVIMEDEUVIMED entdecken
Crossref

Metformin Regulates Cardiac Ferroptosis to Reduce Metabolic Syndrome-Induced Cardiac Dysfunction

Liancheng Xu, Wenwen Li, Yu Chen, Shan Liu, Guodong Liu, Weihuan Luo, Guanyi Cao, Shiping Wang

Applied Biochemistry and Biotechnology · 2025-01 · 197 (1) · 179-193

DOI: 10.1007/s12010-024-05038-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, online erschienen am 06.08.2024. Verfasst von Liancheng Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Suqian First Hospital, No.120 Suzhi Street, Suqian, 223800, Jiangsu Province, China. Hauptthemen laut MEDLINE: Metformin, Ferroptosis, Metabolic Syndrome, Myocardium. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Suqian Sci&Tech Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-fat diet-induced metabolic syndrome (MetS) is closely associated with cardiac dysfunction. Recent research studies have indicated a potential association between MetS and ferroptosis. Furthermore, metformin can alleviate MetS-induced cardiac ferroptosis. Metformin is a classic biguanide anti-diabetic drug that has protective effects on cardiovascular diseases, which extend beyond its indirect glycemic control. This study aimed to assess whether MetS mediates cardiac ferroptosis, thereby causing oxidative stress and mitochondrial dysfunction. The results revealed that metformin can mitigate cardiac reactive oxygen species and mitochondrial damage, thereby preserving cardiac function. Mechanistic analysis revealed that metformin upregulates the expression of cardiac Nrf2. Moreover, Nrf2 downregulation compromises the cardio-protective effects of metformin. In summary, this study indicated that MetS promotes cardiac ferroptosis, and metformin plays a preventive and therapeutic role, partially through modulation of Nrf2 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminFerroptosisMetabolic SyndromeMyocardiumHeart DiseasesAnimalsNF-E2-Related Factor 2Reactive Oxygen SpeciesMaleOxidative StressMiceMyocytes, CardiacRats

Stichwörter der Autor:innen

Cardiac dysfunctionFerroptosisMetabolic syndromeMetforminMitochondrial damageNuclear factor erythroid 2-related factor 2Reactive oxygen species

Substanzen

MetforminNF-E2-Related Factor 2Reactive Oxygen Species

Autor:innen und Institutionen

  • Department of General Surgery, Suqian First Hospital, No.120 Suzhi Street, Suqian, 223800, Jiangsu Province, China.
  • Fujian Medical University, Fuzhou, 350108, China.
  • Department of Nephrology, Suqian First Hospital, Suqian, 223800, China.
  • Department of General Surgery, Suqian First Hospital, No.120 Suzhi Street, Suqian, 223800, Jiangsu Province, China. sqyy1035@163.com.

Förderung

  • Suqian Sci&Tech Program

Zitieren

APA

Xu, L., Li, W., Chen, Y., Liu, S., Liu, G., Luo, W., Cao, G., & Wang, S. (2025). Metformin Regulates Cardiac Ferroptosis to Reduce Metabolic Syndrome-Induced Cardiac Dysfunction. Applied Biochemistry and Biotechnology, 197(1), 179-193. https://doi.org/10.1007/s12010-024-05038-7

Vancouver

Xu L, Li W, Chen Y, Liu S, Liu G, Luo W, et al. Metformin Regulates Cardiac Ferroptosis to Reduce Metabolic Syndrome-Induced Cardiac Dysfunction. Applied Biochemistry and Biotechnology. 2025;197(1):179-193. doi:10.1007/s12010-024-05038-7

BibTeX
@article{Xu2025,
  author = {Xu, Liancheng and Li, Wenwen and Chen, Yu and Liu, Shan and Liu, Guodong and Luo, Weihuan and Cao, Guanyi and Wang, Shiping},
  title = {Metformin Regulates Cardiac Ferroptosis to Reduce Metabolic Syndrome-Induced Cardiac Dysfunction},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2025},
  volume = {197},
  number = {1},
  pages = {179--193},
  doi = {10.1007/s12010-024-05038-7}
}
Kostenlos starten →